Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human fibrinogen for acquired hypofibrinogenemia in chronic liver disease
CTR20263145Phase 3Active
- Sponsor
- Danxia Biological Pharmaceutical
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Fibrinogen human in Acquired fibrinogenopenia, chronic liver disease (CLD), perioperative bleeding, Bleeding, sponsored by Danxia Biological Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
Fibrinogen human
03
Conditions
Acquired fibrinogenopeniachronic liver disease (CLD)perioperative bleedingBleeding
Beyond the preview
Go deeper on CTR20263145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263145.